The pandemic may have spurred big changes in clinical trial design and conduct, but an FDA official says the key to prepping for an agency inspection remains the same.
Finding the right balance of information to send to IRBs during remote trials is a delicate, but crucial, challenge, experts say.
While the imperatives for conducting DCTs have waned, now is not the time to revert to requiring onsite visits for everything, expert says.
The time is ripe for clinical researchers to teach the public what efforts to increase its involvement in trials are really all about.
Don’t sell your site short when competing against the big kids on the block for new trials, expert says.